Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Randomized, Blinded, Controlled Phase I / Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of the Fully Human Anti-tetanus Toxin Monoclonal Antibody A82 / B86 Injection Combination

NCT06360250 is registered in ClinicalTrials.gov with Changchun BCHT Biotechnology Co. as lead sponsor.

NCT NCT06360250
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06360250 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Randomized, Blinded, Controlled Phase I / Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of the Fully Human Anti-tetanus Toxin Monoclonal Antibody A82 / B86 Injection Combination
Lead sponsor
Changchun BCHT Biotechnology Co.
Phase
Phase 1
Overall status
Unknown status
Start date
April 10, 2024
Completion date
October 30, 2024
Enrollment
190 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

clostridium tetanus